CYP19A1 and breast cancer: Aromatase is a key enzyme in estrogen synthesis, and the use of aromatase inhibitors (AIs), such as letrozole, anastrozole and exemestane, in the adjuvant setting is regarded as a standard approach in postmenopausal women with ERα-positive breast cancer [3–5].